A 2:1 randomized, open-label, phase II study of selinexor vs. physician’s choice in older patients with relapsed or refractory acute myeloid leukemia

Kendra Sweet, Bhavana Bhatnagar, Hartmut Döhner, Will Donnellan, Olga Frankfurt, Michael Heuser, Vamsi Kota, Hongtao Liu, Emmanuel Raffoux, Gail J. Roboz, Christoph Röllig, Margaret M. Showel, Stephen A. Strickland, Susana Vives, Shijie Tang, Thaddeus J. Unger, Anita Joshi, Yao Shen, Mariano J. Alvarez, Andrea CalifanoMarsha Crochiere, Yosef Landesman, Michael Kauffman, Jatin Shah, Sharon Shacham, Michael R. Savona, Pau Montesinos

Research output: Contribution to journal › Article › peer-review

9 Scopus citations

Fingerprint

Dive into the research topics of 'A 2:1 randomized, open-label, phase II study of selinexor vs. physician’s choice in older patients with relapsed or refractory acute myeloid leukemia'. Together they form a unique fingerprint.

Medicine & Life Sciences